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Abstract
Background:  HIPK2 (homeodomain-interacting protein kinase 2) has been identified as a nuclear
serine/threonine kinase. A central function of HIPK2 is repressing transcription of homeodomain
containing transcription factors.
Results and Conclusions:  We show here that HIPK2 activates transcription mediated by tumor
suppressor p53 responsive promoter elements. Overexpression of HIPK2 leads to an increase of
p53 protein expression or stability, which becomes enhanced further in the presence of the DNA
damaging drug doxorubicin. The effects of HIPK2 on p53 are not observed with kinase deficient
HIPK2 mutants. However, HIPK2 is not sufficient for phosphorylation of three crucial serine
residues of p53, suggesting that HIPK2-induced p53 activation does not involve phosphorylation of
p53. Instead, HIPK2 leads to a downregulation of p53-induced Mdm2 protein and this may lead to
stabilization of p53. Overexpression of HIPK2 does not lead to a change of Mdm2 mRNA
expression. The data suggest that HIPK2 plays a critical role in p53 mediated cellular responses by
removing the p53 inhibitor protein Mdm2 via modification of the protein itself or its intracellular
movement.
Background
The tumor suppressor protein p53 contributes to the
control of cell cycle checkpoints and apoptosis and is fre-
quently lost or mutated in multiple types of human can-
cers [1]. DNA damaging agents induce p53 accumulation
and induction of p53-mediated transcription [2,3]. Sev-
eral proteins are known to play a crucial role in the stabi-
lization and activation of p53 [4,5]. The association with
murine double minute clone 2 (Mdm2) leads to a suscep-
tibility of p53 for proteolysis [6,7] and thus, p53 protein
levels are regulated post-transcriptionally [8].
Homeodomain-interacting protein kinase 2 (HIPK2) has
been recently described as a member of a family of nucle-
ar kinases that act as co-repressors for homeodomain
transcription factors [9] and it is a potential interaction
partner for interferon type I induced Mx GTPases with
antiviral activity against several RNA viruses [10].
HIPK2 is regulated by the ubiquitin-like protein SUMO-
1 and the covalent SUMO-1 modification correlates with
its localization to nuclear speckles or nuclear dots [11].
Here we address the question whether HIPK2 modifies
Published: 10 August 2001
BMC Molecular Biology 2001, 2:8
Received: 9 May 2001
Accepted: 10 August 2001
This article is available from: http://www.biomedcentral.com/1471-2199/2/8
© 2001 Wang et al; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any non-com-
mercial purpose, provided this notice is preserved along with the article's original URL. For commercial use, contact info@biomedcentral.comBMC Molecular Biology 2001, 2:8 http://www.biomedcentral.com/1471-2199/2/8
transcription regulated by transcription factors other
than homeoproteins.
We found that HIPK2 activates transcription mediated
by p53 specific promoter elements. HIPK2 also enhances
expression levels of p53 protein. Both effects on p53 are
not observed with a kinase defective mutant and large
amino and carboxy-terminal deletion mutants of HIPK2.
The DNA damaging anti-cancer drug doxorubicin en-
hances HIPK2-induced expression or stability of p53.
HIPK2 overexpression downregulates Mdm2 protein
levels. Therefore, the observed effects of HIPK2 on p53
seem to be mediated by Mdm2. We conclude that an im-
portant function of HIPK2 is the stabilization and activa-
tion of p53 by inducing degradation of Mdm2.
Results
HIPK2 activates p53-mediated transcription
Since HIPK2 has been described as a nuclear protein that
interacts with homeodomain containing transcription
factors [9,11], we looked for an influence of HIPK2 on
transcription mediated by several transcription factors
such as p53, NFκ B and Elk1.
The tumorsuppressor p53 is a transcription factor that
binds to DNA and is involved in the cell cycle and apop-
tosis. To test a possible transcriptional transactivation
activity of HIPK2, expression vectors encoding wildtype
or the mutated HIPK2 proteins (AC, AN and K221A)
were transfected into 293 (Fig. 1A) and HeLa (Fig. 1B)
cells together with p53-luc, a luciferase reporter gene un-
der the control of the p53-specific enhancer element
(TGCCTGGACTTGCCTGG)15. The p53-specific enhanc-
er element is derived from the sequence comparison of
promoters of p53-inducible genes [12,13]. HeLa cells
have been found to contain endogenous transcriptionally
active p53 protein by the intrinsic ability to transactivate
p53-responsive promoter elements [14]. In line with this,
endogenous p53 of the HeLa cells used in our experi-
ments had transcriptional activity and wildtype se-
quence (data not shown). Activation of the luciferase
activity by cotransfection of 50 ng of the reporter plas-
mid encoding p53 (pFC-p53) was 250 fold for 293 and
160 fold for HeLa cells, respectively (data not shown).
The luciferase value of vector and p53-luc transfected
cells were standardized for a value of 1 in each assay, to
control for activation of the p53 specific enhancer ele-
ment by endogenous p53. The intrinsic activity of endog-
enous p53 was approximately 20 fold above the blank
controls (data not shown). Wildtype HIPK2 induced a 40
fold increase of p53-mediated transcription in 293 cells
compared to the increase in vector transfected control
cells (Fig. 1A). No such strong increase was observed
with the kinase defective HIPK2 mutant K221A, a car-
boxy-terminal HIPK2 deletion mutant AC or an amino-
terminal deletion mutant AN (Fig. 1A and 1B). But luci-
ferase activity induced by the HIPK2 mutants was above
the vector controls. Protein expression of recombinant
HIPK2 in HeLa cells was shown in Western analysis after
transient transfection of a Flag-tagged wildtype HIPK2
expression construct as described [26] (Fig. 1D). Expres-
sion of overexpressed and endogenous HIPK2 protein in
HeLa cells was not detected by using a polyclonal anti-
HIPK2 antiserum [26] (data not shown).
To test whether HIPK2 activates transcription mediated
by p53 responsive elements via p53, we transiently trans-
fected human Saos2 cells, which lack p53 expression
[15], with different HIPK2 expression constructs (Fig.
1C). Expression of wildtype HIPK2 did not lead to a sig-
nificant increase in luciferase activity compared to its
mutants, K221A and AC, and the vector control. Howev-
er, transfection of 50 ng of pFC-p53 into Saos2 cells re-
sulted in a 200 fold increase in luciferase activity and this
increase was not further enhanced in the presence of
HIPK2 (data not shown). Taken together, HIPK2 acti-
vates transcription mediated by p53 specific promoter
elements and p53 is required for this effect. The en-
hancement of transcription is diminished by different
mutations of HIPK2.
Wildtype HIPK2 leads to an increase of p53 expression or 
stability
Since HIPK2 activated p53-mediated transcription, we
looked whether HIPK2 leads to an increase in the level of
p53 protein after transient transfection of HeLa cells.
Wildtype HIPK2 enhanced protein expression or stabili-
ty of p53 compared to the vector transfected controls
(Fig. 2A). The kinase-defective mutant K221A and the
amino-terminal deletion AN which lacks the kinase do-
main led to a decrease of p53 protein. The carboxy-ter-
minal HIPK2 deletion mutant AC which contains the
kinase part did not influence p53 protein levels (Fig. 2A).
This is a hint that the increase of p53 protein induced by
wildtype HIPK2 could be responsible for the enhanced
transcriptional activity mediated by p53 binding pro-
moter elements (Fig. 1).
Doxorubicin enhances the HIPK2-mediated increase of 
p53 expression or stability
Since p53 is stabilized in response to DNA damage, we
tested whether HIPK2 has an effect on stabilization of
p53 mediated by the DNA damaging drug doxorubicin in
HeLa cells. Doxorubicin induced a significant increase of
the p53 protein level after 6 h in the vector-transfected
controls (Fig. 2B). When cells were transiently transfect-
ed with wildtype HIPK2, the increase of p53 protein was
similar to that observed after 6 h doxorubicin treatment.
The combination of overexpression of HIPK2 and treat-
ment with doxorubicin for 6 h resulted in an increase inBMC Molecular Biology 2001, 2:8 http://www.biomedcentral.com/1471-2199/2/8
p53 protein levels compared to either treatment alone, i.
e. the HIPK2-mediated increase of the p53 protein level
was further enhanced by the addition of doxorubicin
(Fig. 2B).
In summary, these results show that wildtype HIPK2 but
not kinase deficient or severely truncated mutants led to
an increase of p53 protein. Treatment with doxorubicin
for at least 6 h further increased the amount of p53 pro-
tein.
HIPK2 is not sufficient for phosphorylation of serine 15, 
serine 20 and serine 392 of p53
Since HIPK2 contains a serine/threonine kinase domain
and since multiple serine/threonine phosphorylation
sites are present in p53 protein, we used antibodies that
specifically detect single phosphorylated serine residues
of p53 to look for a putative HIPK2-mediated phosphor-
ylation of p53. Upon treatment with doxorubicin, serine
Figure 1
Activation of p53-mediated transcription by HIPK2 overex-
pression. 293 (A), HeLa (B) and Saos2 (C) cells were
cotransfected with a p53-luciferase reporter construct and
the indicated HIPK2 constructs or vector. Results represent
the mean of three independent experiments. Bars, SD. (D)
Western analysis of transient overexpression of Flag-tagged
wildtype HIPK2 in HeLa cells (right lane) compared to vec-
tor-transfected control cells (left lane) with an anti-Flag anti-
body.
Figure 2
Enhancement of p53 protein levels by wildtype HIPK2. HeLa
cells were transiently transfected with the indicated HIPK2
expression constructs. Cellular extracts were analyzed for
p53 expression by Western blotting. The signals correspond-
ing to p53 or phosphorylated p53 (Phospho-p53) are indi-
cated by an arrow. Equal loading was confirmed by reprobing
the blots with an anti-β -actin antibody as shown below. (A)
Cells were left untreated after transfection. (B) 24 h after
transfection, doxorubicin was added to a final concentration
of 0.1 µg/ml for 3 and 6 h as indicated. (C) 24 h after trans-
fection doxorubicin was added to a final concentration of 0.1
µg/ml for 6 h and anti-phospho-p53 (Ser 15)-antibody was
used for detection of phosphorylated serine 15 in p53. wt,
wildtype; vec, vector.BMC Molecular Biology 2001, 2:8 http://www.biomedcentral.com/1471-2199/2/8
15 is phosphorylated in HeLa cells (Fig. 2C). However, no
serine 15 phosphorylation was detected after transient
transfection of HIPK2 in the absence of doxorubicin
treatment. The amount of phosphorylated protein after
doxorubicin treatment reflects the total amount of p53
protein (Fig. 2A, B and 2C), which suggests that almost
all p53 protein present became phosphorylated on serine
15. Since the kinase defective HIPK2 mutant K221A
probably acts in a dominant negative way, the amount of
p53 which was induced by endogenous HIPK2 in the vec-
tor-transfected controls decreased. Similar to the de-
crease in the amount of p53 protein in the presence of the
K221A mutant (Fig. 2A) there was a decrease in phos-
phorylated p53 after treatment with doxorubicin (Fig.
2C). As expected from these findings, overexpression of
the HIPK2 mutants AN and AC yielded less phosphor-
ylated p53 compared to overexpression of wildtype
HIPK2 in the presence of doxorubicin (Fig. 2C). Similar
results were obtained using an antibody against serine
residue 20 (data not shown).
Using an antibody that specifically detects phosphoryla-
tion of serine 392 in p53 we could not detect phosphor-
ylated p53 either in the presence of doxorubicin or
during overexpression of HIPK2 (data not shown). Tak-
en together, HIPK2 is not sufficient for phosphorylation
of p53 at serine residues 15 and 20, where doxorubicin
seems to be required, and for phosphorylation of serine
392.
HIPK2 leads to a decrease of p53-induced Mdm2 expres-
sion
To further characterize the interaction of HIPK2 and
p53, Saos2 cells were transiently cotransfected with con-
structs coding for p53, p53 and wildtype HIPK2 or p53
and the kinase defective HIPK2 mutant K221A together
with pEGFP-Nl coding for a green fluorescence protein
(Fig. 3A). Mdm2 and p53 proteins were not detectable in
Saos2 cells (lane 1). In agreement with previous observa-
tions [16,17], wildtype p53 led to an induction of endog-
enous Mdm2 expression (lane 2). Interestingly, a p53-
mediated induction of Mdm2 expression was not ob-
served in the presence of wildtype HIPK2 (lane 3).
Therefore, HIPK2 overexpression led to a decrease of
p53-induced Mdm2 protein levels. This decrease in
Mdm2 protein was not observed by coexpression of the
kinase defective HIPK2 mutant K221A (lane 4), which
suggests that the kinase domain is necessary for Mdm2
downregulation. Equal protein loading was shown by
reprobing the filters with an antibody detecting β -actin.
pAGFP-Nl was cotransfected in all cases to normalize
overexpression. GFP fluorescence was not significantly
different (Fig. 3B), indicating similar transfection effi-
ciencies.
HIPK2 overexpression does not change Mdm2 mRNA ex-
pression
Next we asked the question whether HIPK2 downregu-
lates Mdm2 by decreasing Mdm2 transcription. We tran-
siently transfected Saos2 cells either with vector alone or
with expression plasmids coding for p53 or HIPK2. In
addition, the plasmid coding for p53 was transiently
transfected in the presence of either wildtype HIPK2 or
the kinase defective HIPK2 K221A mutant (Fig. 4). Rela-
tive Mdm2 mRNA levels were detected by quantitative
TaqMan RT-PCR with sequence specific primers for hu-
man Mdm2 (GenBank accession AF201370). As expect-
ed, p53 led to an approximately 4 fold increase of Mdm2
mRNA levels [16,17]. In contrast, overexpression of
HIPK2 did not lead to a change of Mdm2 mRNA com-
pared to vector transfected controls (Fig. 4). Overexpres-
sion of p53 together with either wildtype HIPK2 or the
kinase defective HIPK2 mutant K221A showed no signif-
icant decrease in p53-induced Mdm2 mRNA levels. Sim-
ilar data were obtained with HeLa cells (data not shown).
Therefore, HIPK2 does not downregulate Mdm2 at the
transcriptional level. It seems that HIPK2 destabilizes
Mdm2 by modifying the Mdm2 protein.
Figure 3
Downregulation of p53-induced Mdm2 by overexpressed
HIPK2. (A) Saos2 cells were transiently cotransfected with
pEGFP-N and expression constructs coding for wildtype 53,
wildtype HIPK2 or the kinase defective HIPK2 mutant
K221A as indicated. After 24 h cells were lysed and analysed
by Western blotting with the indicated antibodies. (B) GFP
fluorescence was measured by quantitative fluorometry to
show equal transfection efficiencies. Background fluores-
cence was set to 1 (lane 0). Fluorescence fold is increased
above background (lanes 1 to 4). Bars, SD.BMC Molecular Biology 2001, 2:8 http://www.biomedcentral.com/1471-2199/2/8
HIPK2 induces Elk1- but not NFκ B-mediated transcription
To test the expected influence of HIPK2 on other tran-
scription factors we used a chimeric protein consisting of
the GAL4 DNA binding domain fused to the activation
domain of the transcription factor Elk1. The transcrip-
tion activator Elk1 becomes phosphorylated and activat-
ed by the MAP (mitogen-activated protein) kinase.
Direct or indirect phosphorylation of this transactivator
by HIPK2 would activate transcription of the luciferase
gene from a reporter plasmid with the GAL4-binding el-
ement. Cotransfection of the trans-activator plasmid
pFA-Elk1, the luciferase reporter plasmid pFR-Luc and
the positive control MEK1 encoding plasmid pFC-MEK1
resulted in an 115 fold increase in luciferase activity in
293 cells compared to pFA2-Elk1 and pFR-Luc transfect-
ed control cells (data not shown). In comparison,
cotransfection of pFA2-Elk1 and the wildtype HIPK2 ex-
pression construct gave only a 6 fold increase (Fig. 5A).
This increase was reduced to 3 fold when the kinase de-
fective HIPK2 mutant K221A was used. However, using
the carboxy-terminal deletion AC with an intact kinase
domain, the increase of luciferase activity was about 17
fold. A possible direct effect of HIPK2 on the luciferase
construct has been tested by cotransfection of wildtype
HIPK2 and pFR-Luc into 293 cells. In this control, the
luciferase activity was similar to the pFR-Luc and pFA2-
Elk1 transfected control cells (data not shown). These re-
sults suggest that HIPK2 may weakly activate the trans-
activator Elk1-GAL4 and that the kinase function of
HIPK2 is necessary for this activation. The carboxy-ter-
minus of HIPK2 may contain inhibitory sequences for
Elk1-phosphorylation. The conclusion is, that HIPK2
seems to activate components of the MAP kinase path-
way. The exact role remains to be elucidated.
In a similar assay, which we have used to study HIPK2-
mediated activation of p53 specific promoter elements,
we looked for a role of HIPK2 in activation of NFκ B-me-
diated transcription. 293 cells were cotransfected with a
luciferase reporter plasmid containing five tandem
NFκ B binding sites and different HIPK2 expression con-
structs (Fig. 5B). Only wildtype HIPK2 activated NFκ B-
mediated transcription slightly but not significantly. No
Figure 4
Quantitative mRNA Expression levels of Mdm2. Saos2 cells
were transiently transfected with the indicated expression
constructs. Mdm2 mRNA expression levels were determined
by TaqMan RT-PCR as described in Materials and Methods.
As internal reference, mRNA expression of GAPDH mRNA
was used. Relative Mdm2 mRNA expression is shown and
Mdm2 mRNA expression of vector transfected cells was set
to 1. Bars, SD.
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Figure 5
Activation of Elk 1-mediated transcription but no activation
of NFκ B by HIPK2 overexpression. (A) 293 cells were
cotransfected with a GAL4-luciferase reporter construct, an
Elk1-GAL4 transactivator expression construct and the indi-
cated HIPK2 constructs or vector. (B) 293 cells were
cotransfected with an NFκ B-luciferase reporter construct
and the indicated HIPK2 constructs or vector. Results repre-
sent the mean of three independent experiments. Bars, SD.BMC Molecular Biology 2001, 2:8 http://www.biomedcentral.com/1471-2199/2/8
effect was seen with the HIPK2 mutants (Fig. 5B). NFκ B-
mediated luciferase activation was 100 fold with a MEK
kinase positive control plasmid (data not shown). The lu-
ciferase values of vector and pNF-κ B-luc transfected
cells were set as 1. Taken together, we conclude that
HIPK2 does not activate NFκ B.
Discussion
HIPK2 enhances p53 activity and p53 expression or stabil-
ity
HIPK2 acts as a co-repressor for homeodomain contain-
ing transcription factors. We show here that HIPK2 has
additional functions, namely the activation of transcrip-
tion mediated by p53 specific promoter elements. There-
by, overexpression of HIPK2 leads to an increase of the
p53 protein level. Neither the transcriptional activation
nor the enhancement of p53 protein amounts is detected
with overexpressed HIPK2 mutants.
The p53 responsive enhancer element becomes activated
by HIPK2 in cell lines with p53 but not in a cell line de-
void of p53 (Fig. 1). We conclude, that the activation of
the enhancer element is indeed mediated by p53 and not
by another transcription factor of the p53 family. The ki-
nase defective mutant of HIPK2, K221A, leads to a de-
crease of p53 protein amounts (Fig 2A). However, this
decrease does not correspond with a further decrease on
p53-mediated transcription compared to HIPK2 mu-
tants AC and AN (Fig. 1A and 1B).
HIPK2 is not sufficient for phosphorylation of crucial ser-
ine residues of p53
The nuclear phosphoprotein p53 is regulated and stabi-
lized by different modifications [3,18], e. g. serine 15
phosphorylation has been detected as prerequisite for
phosphorylation of tyrosine residue 18 [19]. HIPK2
could not activate or stabilize p53 either directly or indi-
rectly by phosphorylation. DNA damaging agents such as
doxorubicin induce increased p53 phosphorylation by as
yet undefined mechanisms. In the presence of wildtype
HIPK2 and doxorubicin, serine residue 15 and 20 of p53
become phosphorylated, which could be either due to
transfected or endogenous HIPK2 of HeLa cells. In the
presence of doxorubicin alone or together with mutants
of HIPK2 serines 15 and 20 could be phosphorylated by
endogenous HIPK2 (Fig. 2C). Thus, we conclude that
HIPK2 is not sufficient for serine 15 and 20 phosphoryla-
tion, for which doxorubicin may be required. HIPK2 is
also not sufficient for phosphorylation of residue 392,
but doxorubicin requirement is excluded. Additional
phosphorylation sites have not been tested since the ab-
solute requirement of phosphorylation for DNA-damage
induced stabilization of p53 remains controversial [20].
Other proteins, which regulate p53, like e. g. Mdm2,
could be the targets for phosphorylation by HIPK2.
Doxorubicin treatment and HIPK2 overexpression show
an additive effect on p53 protein expression or stability
(Fig. 2B). The relative amounts of the increase of the p53
protein levels and the increase in doxorubicin induced
phosphorylation of serine residue 15 are comparable and
give rise to the assumption that the total amount of p53
protein present becomes phosphorylated under doxoru-
bicin treatment. Since p53 has a high turnover rate [4],
the increase of p53 protein levels seems to be due to sta-
bilization of p53 rather than induction of enhancement
of transcription of p53. An increase of p53 mRNA stabil-
ity or translation efficiency could play additional roles.
HIPK2 downregulates Mdm2 protein
HIPK2 may exert all its effects on p53 via Mdm2, since it
leads to a decrease of the p53-induced Mdm2 protein
level (Fig. 3). HIPK2 has no influence on Mdm2 tran-
scription (Fig. 4). Therefore, HIPK2 regulates Mdm2 sta-
bility at the protein level. The most likely mechanism is
serine/threonine phosphorylation of Mdm2 either di-
rectly or indirectly by HIPK2. At present, we did not get
convincing data showing a direct serine/threonine phos-
phorylation of Mdm2 by HIPK2.
Mdm2 shuttles between the nucleus and the cytoplasm
and this nucleo-cytoplasmic shuttling of Mdm2 is essen-
tial for its ability to promote p53 degradation by the cy-
toplasmic proteasome [21]. Mdm2 seems to have a role
in exporting p53 from the nucleus [22,23]. HIPK2 did
not directly interact with either p53 or Mdm2 in yeast
and 293T cells (data not shown). Whether HIPK2 can in-
fluence the shuttling of Mdm2 remains to be clarified.
Effect of HIPK2 on target genes of p53
We have addressed the issue to check expression of de-
scribed downstream targets of p53 at the protein level in
HeLa cells. The best characterized target gene that be-
comes transactivated by p53 is the cyclin/Cdk inhibitor
p21 (Waf1/Cip1) [3]. But we did not detect a significant
increase of expression of p21 (Waf1/Cip1) mediated by
overexpression of HIPK2 or treatment with doxorubicin
in Western blotting analysis. As a positive control 2 µg of
the wildtype p53 expression construct pFC-p53 was tran-
siently transfected and transient overexpression of
wildtype p53 led to a weak increase of p21 (Waf1/Cip1)
expression (data not shown). Western blotting does not
seem to be sensitive enough to detect a significant differ-
ence in p21 expression between vector and wildtype
HIPK2 transfected cells. In the same experimental set-
ting an increase of expression of the pro-apoptotic Bcl2
family member Bax, whose gene has been described as a
p53 target [3], was not detectable (data not shown).
Therefore, induction of p53 target genes seems to be cell
type specific. The recently described p53-dependent pro-BMC Molecular Biology 2001, 2:8 http://www.biomedcentral.com/1471-2199/2/8
apoptotic Bcl-2 family member Noxa [24] is a further
candidate that could be regulated via HIPK2.
In this respect, a further difficulty is that HIPK2 down-
regulates the p53-induced Mdm2 protein level. This may
also be the case for other p53-induced proteins.
Other functions of HIPK2
HIPK2 is also termed PKM (for Mx-interacting protein
kinase) since it has been cloned in a yeast two-hybrid
screen as an interaction partner for the interferon type I-
induced protein MxA, that displays antiviral activity
against a variety of RNA viruses [10]. The nuclear distri-
bution of murine Mx1 is similar to HIPK2/PKM, but a di-
rect interaction of the Mx protein with HIPK2/PKM and
phosphorylation of Mx by HIPK2/PKM could not be
demonstrated so far [10]. HIPK2/PKM phosphorylates
several phosphoproteins expressed in E. coli. This reac-
tion is inhibited by a kinase defective mutant K221W of
HIPK2/PKM. Thereby it was also shown that HIPK2/
PKM is a true serine/threonine kinase, rather then a dual
specificity protein kinase which is able to phosphorylate
both, serine/threonine and tyrosine residues [10].
HIPK2 interacts with the death factor receptor CD95 in
the yeast two-hybrid system [25]. When overexpressed
in mammalian cells it associates with TRADD [26].
TRADD has been described to bind to the tumor necrosis
factor type I and thereby executing essential functions in
signaling [27,28]. Whether HIPK2 plays an important
role in death receptor mediated apoptosis is not clear at
present. Recently, it has been described that HIPK3, a
member of the HIPK family, binds to CD95 and thereby
inhibits c-Jun N-terminal kinase activation [29].
An additional function of HIPK2 may be the activation of
the mitogen-activated protein kinase pathways since we
detected a weak activation of Elk1 mediated transcrip-
tion. The carboxy-terminal deletion of HIPK2 ∆ C aug-
ments the activation of Elk1-mediated transcription in
comparison to wildtype HIPK2. The carboxy-terminal
deletion of HIPK2 ∆ C is equally distributed in the nucle-
us. In contrast, wildtype HIPK2 and the kinase defective
K221A mutant localize to nuclear speckles [25]. This sug-
gests that the equal nuclear distribution of the HIPK2
mutant ∆ C is responsible for the increase in Elk1 mediat-
ed transcription. It has been shown that DNA damage in
addition to stabilization of p53 leads to an activation of a
MAP kinase homolog, the c-Jun N-terminal kinase or
stress activated protein kinase [30].
Conclusions
HIPK2 is a nuclear kinase that activates transcription
mediated by tumor suppressor p53 responsive promoter
elements upon overexpression. Furthermore, it plays a
role in the induction of expression or stability of p53 pro-
tein. Overexpression of HIPK2 does not lead to a change
of Mdm2 mRNA levels, but it leads to a downregulation
of p53-induced Mdm2 protein. Most likely, this HIPK2-
induced decrease of Mdm2 is responsible for the stabili-
zation of p53. The involvement of HIPK2 kinase activity
remains to be identified.
Materials and methods
Cell lines and cell culture
HeLa cells were maintained in RPMI 1640 containing
10% heat-inactivated fetal bovine serum, L-glutamine,
and penicillin/streptomycin (all from Gibco Life Tech-
nologies, Karlsruhe, Germany). The stock solution of
doxorubicin (Amersham-Pharmacia, Freiburg, Germa-
ny) was 2 mg/ml in H20. Human osteosarcoma Saos2
cells and human embryonic kidney 293 cells were cul-
tured in Dulbecco's modified Eagle's medium containing
10% heat-inactivated fetal bovine serum, L-glutamine,
and penicillin/streptomycin (all from Gibco Life Tech-
nologies, Karlsruhe, Germany).
Plasmids, construction of expression plasmids, mutagene-
sis and transient transfection
The full length human HIPK2 cDNA [25] was subcloned
into the EcoR1 and XhoI sites of pcDNA3.1-zeo(+) (Inv-
itrogen, Groningen, The Netherlands). The DNA frag-
ments for the deletion constructs were generated by PCR
using Deep Vent polymerase (New England Biolabs,
Frankfurt, Germany) and primers with appropriate re-
striction sites and epitope tags. Details about the used
primers can be obtained upon request. The carboxy-ter-
minal HIPK2 deletion AC contains amino acids until po-
sition 527, the amino-terminal deletion AN from amino
acid position 559. The PCR fragments were subcloned in
pBSIIsk(-) (Stratagene, Offenbach, Germany), se-
quenced using an automated sequencer (Applied Biosys-
tem, Langen, Germany) and inserted into pcDNA3
(Invitrogen, Groningen, The Netherlands). The point
mutant HIPK2 K221A was generated using the Quick-
ChangeTM kit (Stratagene, Offenbach, Germany) ac-
cording to the manufacturer's instructions. The plasmid
pEGFP-Nl coding for a green fluorescent protein was ob-
tained from Clontech (Heidelberg, Germany). The plas-
mid coding for wildtype p53 was a kind gift from M. Oren
(The Weizmann Institute of Science, Israel).
HeLa and Saos2 cells were transiently transfected by us-
ing the GenePORTER TM Transfection Reagent (Gene
Therapy Systems, San Diego, CA, USA) according to the
protocol of the manufacturer. Transient transfections of
293 cells were performed by the calcium phosphate
method. Prior to transfection approximately 5 ×  105 cells
were plated onto a 60 mm dishes to a confluency of 20%.
Cells were harvested at 20–30 h following transfectionBMC Molecular Biology 2001, 2:8 http://www.biomedcentral.com/1471-2199/2/8
and lysed in 500 µl of lysis buffer (20 mM HEPES, pH
7.4, 150 mM NaCl, 5 mM EDTA, 10 % glycerol, 0.5% Tri-
ton X-100, 20 µl/ml protease inhibitor cocktail (Sigma,
Taufkirchen, Germany).
Elk1 activation assay
293 cells have been transiently cotransfected with 1 µg
pFR-Luc (Stratagene, Offenbach, Germany) and 50 ng
pFA2-Elk1 (PathDetect in vivo signal transduction path-
way trans-reporting systems, Stratagene, Offenbach,
Germany) with or without 1 µg of the indicated plasmids
coding for HIPK2. 50 ng of pFC-MEK1 (Stratagene, Of-
fenbach, Germany) served as positive control. After 24 h
cells were starved for 8 h. Then lysophosphatidic acid
(Sigma, Taufkirchen, Germany) was added to a final con-
centration of 10 µM for 30 min. Cells lysis and measure-
ment of luciferase activity were done according to the
instructions for the luciferase assay system (Promega,
Mannheim, Germany).
p53 and NFκ B activation assay
293 or HeLa cells have been transiently cotransfected
with 1 µg pNF-κ B-Luc (PathDetect in vivo signal trans-
duction pathway cis-reporting systems, Stratagene, Of-
fenbach, Germany) with or without 1 µg of the indicated
plasmids coding for HIPK2. 50 ng of pFC-MEKK (Strat-
agene, Offenbach, Germany) served as positive control
for activation of NFκ B-mediated transcription. For
measuring activation of p53, 1 µg pf p53-Luc (PathDetect
in vivo signal transduction pathway cis-reporting sys-
tems, Stratagene, Offenbach, Germany) has been used
for cotransfection instead of pNF-κ B-Luc. The positive
control for activation of p53-mediated transcription was
50 ng pFC-p53 (Stratagen, Offenbach, Germany), which
contains the p53 cDNA under the control of a cytomega-
lovirus promoter. Cells were collected after 24 h. Cell
lysis and measurement of luciferase activity were done
according to the instructions for the luciferase assay sys-
tem (Promega, Mannheim, Germany).
Western blotting
HeLa or Saos2 cells were transiently transfected with ei-
ther the vector pcDNA3.1-zeo+ (Invitrogen, Groningen,
The Netherlands), the p53 (pFC-p53, Stratagene, Offen-
bach, Germany) or the HIPK2 expression construct.
Cells were harvested 20–30 h following transfection and
lysed in 100 µl of lysis buffer (20 mM HEPES, pH 7.4,
150 mM NaCl, 5 mM EDTA, 10% glycerol, 0.5% Triton X-
100, 20 µl/ml protease inhibitor cocktail (Sigma,
Taufkirchen, Germany)). The protein concentration was
determined by the BCA-Pierce-Protein Assay kit accord-
ing to the protocol of the manufacturer. For Western
analysis, 20–30 µg of protein was separated on 10–20%
gradient gels (Bio-Rad, Hercules, CA, USA) and blotted
onto nitrocellulose membranes (Amersham-Pharmacia,
Freiburg, Germany) according to standard protocols.
The monoclonal anti-p53 antibody DO-7 and the mono-
clonal anti-p21 (Waf1/Cip1) antibody SX118 were pur-
chased from PharMingen International (Hamburg,
Germany), the polyclonal anti-Bax antibody Ab-1 (150-
165) from Calbiochem (Schwalbach, Germany), the poly-
clonal phospho-p53 (Ser 15) (Ab-3), phospho-p53 (Ser
392) (Ab-4) and the monoclonal Mdm2 (Ab-1) antibod-
ies from OncogeneTM (Schwalbach, Germany) research
products, the polyclonal phospho-p53 (Ser 20) from Ne-
wEngland Biolabs (Frankfurt, Germany), the mono-
clonal anti-Flag antibody M2 from Stratagene
(Offenbach, Germany) and the monoclonal anti-β -actin
antibody AC-15 from Sigma (Taufkirchen, Germany). An
anti-mouse secondary IgG1 antibody coupled to horse-
raddish peroxidase (Santa Cruz Biotechnology, Heidel-
berg. Germany) was used at a dilution 1:5000. Antibody
reactive bands were detected by using the enhanced
chemiluminescence Western detection system (Amer-
sham-Pharmacia, Freiburg, Germany). Fluorometric
protein quantification was done by excitation at 485 nm
and emission measurement at 510 nm of cellular extracts
in a fluorometer (Victor, Wallac, Freiburg, Germany).
For reprobing, membranes were treated with stripping
buffer (62.5 mM Tris-HCl pH 6.7, 2% SDS, 100 mM β -
mercaptoethanol) at 50°C for 30 min.
Quantitative TaqMan RT-PCR
Quantitative TaqMan RT-PCR (real time PCR) was car-
ried out by Toplab GmbH (München, Germany) by using
an ABI PRISM Sequence Detection System 7700. Se-
quence specific internal Primers were labelled with
FAM/TAMRA. Endogenous reference mRNA was hu-
man GAPDH mRNA.
List of Abbreviations
HIPK2, homeodomain-interacting protein kinase 2;
MAP, mitogen-activated protein; Mdm2, murine double
minute clone 2.
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